(ZTS) Zoetis - Overview
Stock: Medicines, Vaccines, Diagnostics, Parasiticides, Nutritionals
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.76% |
| Yield on Cost 5y | 1.37% |
| Yield CAGR 5y | 18.92% |
| Payout Consistency | 100.0% |
| Payout Ratio | 32.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.2% |
| Relative Tail Risk | -5.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.06 |
| Alpha | -37.46 |
| Character TTM | |
|---|---|
| Beta | 0.634 |
| Beta Downside | 0.558 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.89% |
| CAGR/Max DD | -0.21 |
Description: ZTS Zoetis January 28, 2026
Zoetis Inc. (NYSE: ZTS) develops, manufactures, and markets a broad portfolio of animal-health products-including medicines, vaccines, diagnostics, biodevices, genetic tests, and precision-health solutions-for livestock (cattle, swine, poultry, fish, sheep) and companion animals (dogs, cats, horses). Its customers span veterinarians, livestock producers, and pet owners, and the firm leverages a partnership with Blacksmith Medicines to explore novel animal-health antibiotics.
Key recent metrics (FY 2024): revenue of $7.2 billion, up 5.1 % YoY, driven by a 7 % increase in companion-animal sales and a 3 % rise in livestock-product sales; adjusted EPS of $6.84, reflecting a 4 % margin expansion after cost-efficiency initiatives. The global animal-health market is projected to grow ~5 % CAGR through 2028, underpinned by rising protein demand in emerging economies and sustained pet-care spending growth (U.S. pet industry spending reached $136 billion in 2023, a 6 % YoY rise). Zoetis’s R&D pipeline includes 12 late-stage candidates, with three expected to launch by 2025, which could lift its long-term growth trajectory if regulatory approvals materialize.
Note: These figures rely on Zoetis’s most recent Form 10-K and industry forecasts; actual performance may diverge due to macro-economic volatility, regulatory changes, or competitive pressures.
For a deeper quantitative assessment, consider exploring Zoetis’s valuation and risk profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.65b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -1.30 > 1.0 |
| NWC/Revenue: 50.82% < 20% (prev 50.04%; Δ 0.78% < -1%) |
| CFO/TA 0.19 > 3% & CFO 2.92b > Net Income 2.65b |
| Net Debt (5.19b) to EBITDA (4.05b): 1.28 < 3 |
| Current Ratio: 3.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (443.2m) vs 12m ago -2.27% < -2% |
| Gross Margin: 70.63% > 18% (prev 0.68%; Δ 6994 % > 0.5%) |
| Asset Turnover: 63.67% > 50% (prev 63.75%; Δ -0.07% > 0%) |
| Interest Coverage Ratio: 15.42 > 6 (EBITDA TTM 4.05b / Interest Expense TTM 231.0m) |
Altman Z'' 7.99
| A: 0.32 (Total Current Assets 6.58b - Total Current Liabilities 1.81b) / Total Assets 15.16b |
| B: 0.90 (Retained Earnings 13.59b / Total Assets 15.16b) |
| C: 0.24 (EBIT TTM 3.56b / Avg Total Assets 14.76b) |
| D: 1.31 (Book Value of Equity 12.78b / Total Liabilities 9.76b) |
| Altman-Z'' Score: 7.99 = AAA |
Beneish M -3.02
| DSRI: 1.06 (Receivables 1.54b/1.41b, Revenue 9.40b/9.15b) |
| GMI: 0.97 (GM 70.63% / 68.49%) |
| AQI: 0.97 (AQ_t 0.31 / AQ_t-1 0.32) |
| SGI: 1.03 (Revenue 9.40b / 9.15b) |
| TATA: -0.02 (NI 2.65b - CFO 2.92b) / TA 15.16b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of ZTS shares?
Over the past week, the price has changed by +0.62%, over one month by -0.84%, over three months by -12.71% and over the past year by -26.67%.
Is ZTS a buy, sell or hold?
- StrongBuy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZTS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 154.8 | 24% |
| Analysts Target Price | 154.8 | 24% |
| ValueRay Target Price | 118.5 | -5.1% |
ZTS Fundamental Data Overview January 29, 2026
P/E Forward = 18.8324
P/S = 5.8934
P/B = 10.1168
P/EG = 2.3261
Revenue TTM = 9.40b USD
EBIT TTM = 3.56b USD
EBITDA TTM = 4.05b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.35b USD (from shortTermDebt, last fiscal year)
Debt = 7.27b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.19b USD (from netDebt column, last quarter)
Enterprise Value = 60.57b USD (55.38b + Debt 7.27b - CCE 2.08b)
Interest Coverage Ratio = 15.42 (Ebit TTM 3.56b / Interest Expense TTM 231.0m)
EV/FCF = 27.04x (Enterprise Value 60.57b / FCF TTM 2.24b)
FCF Yield = 3.70% (FCF TTM 2.24b / Enterprise Value 60.57b)
FCF Margin = 23.84% (FCF TTM 2.24b / Revenue TTM 9.40b)
Net Margin = 28.21% (Net Income TTM 2.65b / Revenue TTM 9.40b)
Gross Margin = 70.63% ((Revenue TTM 9.40b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 71.54% (prev 72.28%)
Tobins Q-Ratio = 4.00 (Enterprise Value 60.57b / Total Assets 15.16b)
Interest Expense / Debt = 0.80% (Interest Expense 58.0m / Debt 7.27b)
Taxrate = 18.71% (166.0m / 887.0m)
NOPAT = 2.90b (EBIT 3.56b * (1 - 18.71%))
Current Ratio = 3.64 (Total Current Assets 6.58b / Total Current Liabilities 1.81b)
Debt / Equity = 1.35 (Debt 7.27b / totalStockholderEquity, last quarter 5.40b)
Debt / EBITDA = 1.28 (Net Debt 5.19b / EBITDA 4.05b)
Debt / FCF = 2.32 (Net Debt 5.19b / FCF TTM 2.24b)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.96% (Net Income 2.65b / Total Assets 15.16b)
RoE = 53.56% (Net Income TTM 2.65b / Total Stockholder Equity 4.95b)
RoCE = 29.64% (EBIT 3.56b / Capital Employed (Equity 4.95b + L.T.Debt 7.07b))
RoIC = 24.85% (NOPAT 2.90b / Invested Capital 11.65b)
WACC = 7.37% (E(55.38b)/V(62.65b) * Re(8.25%) + D(7.27b)/V(62.65b) * Rd(0.80%) * (1-Tc(0.19)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.85%
[DCF Debug] Terminal Value 82.76% ; FCFF base≈2.27b ; Y1≈2.67b ; Y5≈4.08b
Fair Price DCF = 168.9 (EV 79.62b - Net Debt 5.19b = Equity 74.43b / Shares 440.7m; r=7.37% [WACC]; 5y FCF grow 18.89% → 2.90% )
EPS Correlation: -16.56 | EPS CAGR: -46.76% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.34 | Revenue CAGR: 5.45% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.58 | Chg30d=+0.008 | Revisions Net=-2 | Analysts=10
EPS next Year (2026-12-31): EPS=6.80 | Chg30d=+0.022 | Revisions Net=-4 | Growth EPS=+7.3% | Growth Revenue=+5.0%